干扰素β-1b治疗复发缓解型多发性硬化的疗效
发布时间：2018-12-09 18:05
【摘要】：目的探讨干扰素(IFN)β-1b用于治疗中国东北地区复发缓解型多发性硬化(RRMS)患者的临床疗效。方法对21例确诊的RRMS患者给予皮下注射IFNβ-1b治疗并随访1年,观察患者扩展的残疾状况评分(EDSS)、头颅磁共振成像(MRI)T2加权像病灶及Gd-DTPA强化病灶数量、汉密尔顿抑郁量表(HAMD)评分、EDSS评分与专用生活质量(MSQOL-54)量表评分相关性及使用IFNβ-1b前后的年复发次数,同时观察药物不良反应。结果 21例患者治疗1年前后神经功能障碍改善,EDSS评分比较差异显著(P0.05);MS患者治疗前后EDSS评分与生活质量呈负相关(r=-0.808,0.755),生活质量有一定改善;头颅MRI新增的T2上及Gd强化病灶数较治疗前减少(P0.05);应用IFNβ-1b 1年前后复发的次数,差异有统计学意义(P0.005);治疗1年前后HAMD评分比较差异无统计学意义(P=0.171)。结论 IFNβ-1b对于RRMS有较好的疗效,延缓临床神经功能障碍程度,改善生活质量,降低复发,减少颅内新发病灶数目,未明显加重抑郁状态;副作用多为应用初期一过性且可耐受。
[Abstract]:Objective to investigate the clinical efficacy of interferon (IFN) 尾-1b in the treatment of recurrent and remission multiple sclerosis (RRMS) patients in Northeast China. Methods Twenty-one patients with RRMS were treated with subcutaneous injection of IFN 尾 -1b and followed up for one year. The number of (MRI) T2-weighted lesions and Gd-DTPA enhanced lesions in (EDSS), head magnetic resonance imaging (EDSS),) were observed. The (HAMD) score, EDSS score and MSQOL-54 score of Hamilton Depression scale were correlated with the number of annual recurrence before and after IFN 尾 -1b use, and the adverse drug reactions were observed at the same time. Results the neurological dysfunction was improved in 21 patients before and after one year treatment, and the difference of EDSS score was significant (P0.05). The EDSS score was negatively correlated with the quality of life (r = 0.808, 0.755), and the quality of life was improved to some extent. The number of enhanced lesions on T2 and Gd increased by MRI was lower than that before treatment (P0.05), and the number of recurrence before and after 1 year of IFN 尾 -1b was significantly different (P0.005). There was no significant difference in HAMD score before and after treatment (P < 0. 171). Conclusion IFN 尾 -1b has a good effect on RRMS, delaying the degree of clinical neurological dysfunction, improving the quality of life, reducing the recurrence, reducing the number of new intracranial lesions, and not exacerbating the depression state. The side effects were transient and tolerable in the early stage of application.
【作者单位】： 吉林大学中日联谊医院神经内一科;吉林大学中日联谊医院放射线科;邯郸市第一医院神经内科;
【基金】：吉林省科技发展计划国际科技合作项目(20110719)
【分类号】：R744.51
本文编号：2369808
[Abstract]:Objective to investigate the clinical efficacy of interferon (IFN) 尾-1b in the treatment of recurrent and remission multiple sclerosis (RRMS) patients in Northeast China. Methods Twenty-one patients with RRMS were treated with subcutaneous injection of IFN 尾 -1b and followed up for one year. The number of (MRI) T2-weighted lesions and Gd-DTPA enhanced lesions in (EDSS), head magnetic resonance imaging (EDSS),) were observed. The (HAMD) score, EDSS score and MSQOL-54 score of Hamilton Depression scale were correlated with the number of annual recurrence before and after IFN 尾 -1b use, and the adverse drug reactions were observed at the same time. Results the neurological dysfunction was improved in 21 patients before and after one year treatment, and the difference of EDSS score was significant (P0.05). The EDSS score was negatively correlated with the quality of life (r = 0.808, 0.755), and the quality of life was improved to some extent. The number of enhanced lesions on T2 and Gd increased by MRI was lower than that before treatment (P0.05), and the number of recurrence before and after 1 year of IFN 尾 -1b was significantly different (P0.005). There was no significant difference in HAMD score before and after treatment (P < 0. 171). Conclusion IFN 尾 -1b has a good effect on RRMS, delaying the degree of clinical neurological dysfunction, improving the quality of life, reducing the recurrence, reducing the number of new intracranial lesions, and not exacerbating the depression state. The side effects were transient and tolerable in the early stage of application.
【作者单位】： 吉林大学中日联谊医院神经内一科;吉林大学中日联谊医院放射线科;邯郸市第一医院神经内科;
【基金】：吉林省科技发展计划国际科技合作项目(20110719)
【分类号】：R744.51
【相似文献】
相关期刊论文 前1条
1 张红;高血压伴糖尿病致腔隙性脑梗死临床研究[J];四川医学;2005年10期
，本文编号：2369808
本文链接：https://www.wllwen.com/yixuelunwen/nfm/2369808.html
最近更新
教材专著
